Benjamin Hadida

Co-Founder & Chief Executive Officer Exeliom Biosciences

Benjamin Hadida is the Co-founder & CEO of Exeliom Biosciences, a clinical-stage immunotherapy company based in France. Exeliom is advancing EXL01, a first-in-class, oral, microbiome-derived immunomodulator that targets NOD2 to enhance responses to immune checkpoint inhibitors and restore immune balance in inflammatory disease. Under Benjamin’s leadership, the company has raised $29M+, built a pilot manufacturing unit, and launched multiple Phase 2 trials across oncology, inflammatory bowel diseases and infectious diseases. His background spans investment banking (UBS), venture capital (Pacific Channel), pharma regulatory (Amgen), biotech operations (Theravectys), and academic research (Vision Institute, Paris). He holds an MSc in Management (ESSEC – Grand Ecole) and an MSc in Molecular & Cellular Biology (Sorbonne University).

Seminars

Wednesday 28th January 2026
Advancing EXL01 Through Clinical Trials & Mechanistic Discovery to Enable Immune Modulation Across Diseases
8:30 am
  • Sharing updates from EXL01’s active Phase II trials in gastric cancer, NSCLC, hepatocellular carcinoma, Crohn’s disease, and C. difficile infection
  • Present early clinical signals from investigator-led studies, including preliminary data in infection and IBD
  • Highlight EXL01’s NOD2-targeted mechanism enabling immune modulation without gut colonisation
Benjamin Hadida - Exeliom